Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Glioblastoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Head and Neck Neoplasms 2Gliosarcoma 2Glioma 2Colorectal Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Supratentorial Neoplasms 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Bronchiolitis Obliterans Syndrome 1Astrocytoma 1

Interventions

Blood Specimen Collection 3ibrutinib 2Rituximab 2Imatinib Mesylate 2ziconotide 1ruxolitinib 1ponatinib 1ofatumumab 1nilotinib 1lonafarnib 1fludarabine 1bosutinib 1Surveys and Questionnaires 1Specimen Handling 1SLC25A33 protein, human 1Povidone-Iodine 1Physical Therapy Modalities 1Pentostatin 1Lenalidomide 1Dasatinib 1Cyclophosphamide 1Bone Marrow Transplantation 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bronchiolitis Obliterans Syndrome × lonafarnib × Clear all
NCT00038597 2018-10-30

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

M.D. Anderson Cancer Center

Phase 2 Completed
13 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡